Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SISTAR: Stratifying Immunosuppression to Allogenic Risk
2025-525091-29-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of belatacept in Kidney allograft status (RTx) (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Biopsy-proven rejection (Banff ≥1A) within the one-year intervention phase and Occurrence of de novo donor-specific antibodies (dnDSAs) with MFI > 1000 within the one-year intervention phase. Planned start Oct 2026; status: authorised.
02
Drugs
belatacept
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2025-525091-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525091-29-00.